MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive Glioblastoma: The DIRECTOR Trial

Michael Weller*, Ghazaleh Tabatabai, Bärbel Kästner, Jörg Felsberg, Joachim P. Steinbach, Antje Wick, Oliver Schnell, Peter Hau, Ulrich Herrlinger, Michael C. Sabel, Hans Georg Wirsching, Ralf Ketter, Oliver Bähr, Michael Platten, Jörg C. Tonn, Uwe Schlegel, Christine Marosi, Roland Goldbrunner, Roger Stupp, Krisztian HomicskoJosef Pichler, Guido Nikkhah, Jürgen Meixensberger, Peter Vajkoczy, Spyros Kollias, Johannes Hüsing, Guido Reifenberger

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

210 Scopus citations

Fingerprint

Dive into the research topics of 'MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive Glioblastoma: The DIRECTOR Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences